Xu Xiao-Le, Ji Hui, Gu Shu-Yi, Shao Qin, Huang Qiu-Ju, Cheng Yan-Ping
Department of Pharmacology, China Pharmaceutical University, 24 Tong Jia Xiang, 210009, Nanjing, PR China.
Eur J Pharmacol. 2007 Jul 30;568(1-3):203-12. doi: 10.1016/j.ejphar.2007.04.007. Epub 2007 Apr 19.
Astragaloside IV, the primary pure saponin isolated from Astragalus membranaceus has been found to have potent cardioprotective effects. In this study, we aim to investigate if the beneficial effects of astragaloside IV on cardiac function are associated with improvement in sarcoplasmic reticulum Ca(2+)-pump function in myocardial injury in vivo. Myocardial injury in rats was induced by subcutaneous injection of a high dose of isoproterenol, and the therapeutic effect of astragaloside IV was observed. Isoproterenol-treated rats showed widespread subendocardial necrosis, a rise in serum lactate dehydrogenase and creatine kinase, formation of lipid oxide product malondialdehyde and inhibition of left ventricular diastolic and systolic function, which suggested severe myocardial injury and acute heart failure. Moreover, sarcoplasmic reticulum Ca(2+)-uptake ability and Ca(2+)-ATPase (SERCA2a) activity were significantly reduced. And the level of SERCA2a mRNA and protein expression was also markedly decreased, associated with a decrease in Ser(16)-phosphorylated phospholamban protein expression, while total phospholamban level was unchanged in the isoproterenol-treated group compared with controls. However, these biochemical and hemodynamic changes in the acute failing hearts were prevented by treatment of isoproterenol-induced rats with astragaloside IV. Likewise, the observed reductions in sarcoplasmic reticulum Ca(2+)-pump function as well as in SERCA2a mRNA and protein levels and the phosphorylation level of phospholamban in the injured hearts were attenuated by astragaloside IV treatment. These results suggest that the beneficial effect of astragaloside IV on isoproterenol-induced myocardial injury may be due to its ability to prevent changes of SERCA2a and Ser(16)-phosphorylated phospholamban protein expression and, thus, may prevent the depression in sarcoplasmic reticulum Ca(2+) transport and improve cardiac function.
黄芪甲苷IV是从黄芪中分离出的主要纯皂苷,已发现其具有强大的心脏保护作用。在本研究中,我们旨在探讨黄芪甲苷IV对心脏功能的有益作用是否与改善体内心肌损伤时肌浆网Ca(2+)泵功能有关。通过皮下注射高剂量异丙肾上腺素诱导大鼠心肌损伤,并观察黄芪甲苷IV的治疗效果。异丙肾上腺素处理的大鼠出现广泛的心内膜下坏死、血清乳酸脱氢酶和肌酸激酶升高、脂质氧化产物丙二醛形成以及左心室舒张和收缩功能抑制,这表明存在严重的心肌损伤和急性心力衰竭。此外,肌浆网Ca(2+)摄取能力和Ca(2+)-ATP酶(SERCA2a)活性显著降低。并且SERCA2a mRNA和蛋白表达水平也明显下降,同时与Ser(16)磷酸化受磷蛋白表达降低相关,而异丙肾上腺素处理组与对照组相比,总受磷蛋白水平未发生变化。然而,用黄芪甲苷IV治疗异丙肾上腺素诱导的大鼠可预防急性衰竭心脏中的这些生化和血流动力学变化。同样,黄芪甲苷IV治疗可减轻受损心脏中观察到的肌浆网Ca(2+)泵功能以及SERCA2a mRNA和蛋白水平以及受磷蛋白磷酸化水平的降低。这些结果表明,黄芪甲苷IV对异丙肾上腺素诱导的心肌损伤的有益作用可能归因于其预防SERCA2a和Ser(16)磷酸化受磷蛋白表达变化的能力,从而可能预防肌浆网Ca(2+)转运的抑制并改善心脏功能。